In a comprehensive study of 124 human melanoma cases that included mutations in BRAF and NRAS, whole-genome and targeted sequencing analyses of tumor samples revealed that variable responses to treatment among samples from the same patient may be attributable to differential mutation frequencies and sample-specific genetic modifications [27]. The gene discussed is NRAS; the disease is melanoma.